Selective targeting of antiapoptotic BCL-2 proteins in cancer

Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer

(2017) Jeroen E Guikema et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Pro-apoptotic effects of lipid oxidation products: HNE at the crossroads of NF-κB pathway and anti-apoptotic Bcl-2

(2017) Ahmet Can Timucin et al.   FREE RADICAL BIOLOGY AND MEDICINE

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

(2017) Avi Ashkenazi et al.   NATURE REVIEWS DRUG DISCOVERY

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

(2017) Delphine Merino et al.   Science Translational Medicine

A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.

(2017) M. Puglisi et al.   JOURNAL OF CLINICAL ONCOLOGY

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia

(2016) S. L. Khaw et al.   BLOOD

S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our Quiver

(2016) Anthony Letai   CANCER CELL

Mechanism of Mcl-1 Conformational Regulation Upon Small Molecule Binding Revealed by Molecular Dynamic Simulation

(2016) Anhui Wang et al.   Chemical Biology & Drug Design

Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates

(2016) Brandon Drennen et al.   ChemMedChem

Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoprotein

(2016) Maryanna E. Lanning et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise

(2016) Kristopher A. Sarosiek et al.   FEBS Journal

A NOXA/MCL-1 Imbalance Underlies Chemoresistance of Malignant Rhabdoid Tumor Cells

(2016) Kazutaka Ouchi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

(2016) Stephan Stilgenbauer et al.   LANCET ONCOLOGY

Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)

(2016) V M Patel et al.   LEUKEMIA

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

(2016) E. A. Punnoose et al.   MOLECULAR CANCER THERAPEUTICS

The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737

(2016) Cécile Pétigny-Lechartier et al.   MOLECULAR CANCER THERAPEUTICS

BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics

(2016) R. S. Soderquist et al.   MOLECULAR CANCER THERAPEUTICS

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia

(2015) R. Pan et al.   BLOOD

Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing

(2015) Jasper E. Neggers et al.   CHEMISTRY & BIOLOGY

Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy

(2015) Maja Sochalska et al.   FEBS Journal

Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity

(2015) Milan Bruncko et al.   JOURNAL OF MEDICINAL CHEMISTRY

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

(2015) Thomas J. Kipps et al.   LEUKEMIA & LYMPHOMA

Myeloid cell leukemia-1 promotes epithelial-mesenchymal transition of human gastric cancer cells

(2015) WAN-SIK LEE et al.   ONCOLOGY REPORTS

Bh3 induced conformational changes in Bcl-Xlrevealed by crystal structure and comparative analysis

(2015) Sreekanth Rajan et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

BCL-2 is dispensable for thrombopoiesis and platelet survival

(2015) M A Debrincat et al.   Cell Death & Disease

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

(2015) D C Phillips et al.   Blood Cancer Journal

Mcl-1 is an important therapeutic target for oral squamous cell carcinomas

(2015) Santanu Maji et al.   Oncotarget

Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner

(2015) Shankar Varadarajan et al.   Oncotarget

Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner

(2015) Irina Kiprianova et al.   NEOPLASIA

Necroptosis Interfaces with MOMP and the MPTP in Mediating Cell Death

(2015) Jason Karch et al.   PLoS One

RFX1–dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells

(2015) Jung-Chen Su et al.   Oncotarget

Bcl-2 family members: Dual regulators of apoptosis and autophagy

(2014) Beth Levine et al.   Autophagy

Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity

(2014) R. W. Rooswinkel et al.   BLOOD

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia

(2014) S. Peirs et al.   BLOOD

Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression

(2014) Kenichiro Doi et al.   CANCER BIOLOGY & THERAPY

Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature

(2014) Omar Abdel-Rahman et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression

(2014) D. Champa et al.   ENDOCRINE-RELATED CANCER

Gossypol Increases Expression of the Pro-apoptotic BH3-only Protein NOXA through a Novel Mechanism Involving Phospholipase A2, Cytoplasmic Calcium, and Endoplasmic Reticulum Stress

(2014) Ryan S. Soderquist et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Anti-Apoptotic Bcl-2 Family Member Mcl-1 Promotes T Lymphocyte Survival at Multiple Stages

(2014) I. Dzhagalov et al.   JOURNAL OF IMMUNOLOGY

Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199

(2014) X Niu et al.   LEUKEMIA

Ex vivoactivity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

(2014) James M. Bogenberger et al.   LEUKEMIA & LYMPHOMA

Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells

(2014) GUAN WANG et al.   ONCOLOGY REPORTS

Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts

(2014) Fariba Némati et al.   PLoS One

BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo

(2014) Longchuan Bai et al.   PLoS One

Targeting BCL2 for the Treatment of Lymphoid Malignancies

(2014) Mary Ann Anderson et al.   SEMINARS IN HEMATOLOGY

Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer

(2014) W Nakajima et al.   Cell Death & Disease

Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer

(2014) Y Loriot et al.   Cell Death & Disease

The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin

(2014) P Geserick et al.   Cell Death & Disease

Single Diastereomer of a Macrolactam Core Binds Specifically to Myeloid Cell Leukemia 1 (MCL1)

(2014) Chao Fang et al.   ACS Medicinal Chemistry Letters

Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199

(2014) T. N. Chonghaile et al.   Cancer Discovery

Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia

(2013) B. Koss et al.   BLOOD

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

(2013) C. J. Vandenberg et al.   BLOOD

ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets

(2013) Meike Vogler et al.   BRITISH JOURNAL OF HAEMATOLOGY

AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia

(2013) Aneel Paulus et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer

(2013) François Vaillant et al.   CANCER CELL

Evaluation and critical assessment of putative MCL-1 inhibitors

(2013) S Varadarajan et al.   CELL DEATH AND DIFFERENTIATION

Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction

(2013) X. Wang et al.   GENES & DEVELOPMENT

BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines

(2013) N M Anderson et al.   LEUKEMIA

Glycolysis Inhibition Sensitizes Non-Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation

(2013) S. M. Kim et al.   MOLECULAR CANCER THERAPEUTICS

A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo

(2013) F. Abulwerdi et al.   MOLECULAR CANCER THERAPEUTICS

BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response

(2013) Kristopher A. Sarosiek et al.   MOLECULAR CELL

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

(2013) Peter E. Czabotar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Direct activation of full-length proapoptotic BAK

(2013) Elizaveta S. Leshchiner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mitochondria: gatekeepers of response to chemotherapy

(2013) Kristopher A. Sarosiek et al.   TRENDS IN CELL BIOLOGY

Multiple Functions of BCL-2 Family Proteins

(2013) J. M. Hardwick et al.   Cold Spring Harbor Perspectives in Biology

Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines

(2013) J M Eichhorn et al.   Cell Death & Disease

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

(2013) R. Pan et al.   Cancer Discovery

Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells

(2012) D. Merino et al.   BLOOD

Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency

(2012) Guo Wei et al.   CANCER CELL

BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions

(2012) Victoria Del Gaizo Moore et al.   CANCER LETTERS

Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML

(2012) Thanh-Trang Vo et al.   CELL

Molecular mechanisms of sorafenib action in liver cancer cells

(2012) Melchiorre Cervello et al.   CELL CYCLE

A Competitive Stapled Peptide Screen Identifies a Selective Small Molecule that Overcomes MCL-1-Dependent Leukemia Cell Survival

(2012) Nicole A. Cohen et al.   CHEMISTRY & BIOLOGY

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

(2012) C. M. Rudin et al.   CLINICAL CANCER RESEARCH

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

(2012) S. P. Glaser et al.   GENES & DEVELOPMENT

Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update

(2012) Angela Gauthier et al.   HEPATOLOGY RESEARCH

Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation

(2012) Kenichiro Doi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis

(2012) Congcong He et al.   NATURE

Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration

(2012) Rhonda M. Perciavalle et al.   NATURE CELL BIOLOGY

Minor cell-death defects but reduced tumor latency in mice lacking the BH3-only proteins Bad and Bmf

(2012) F Baumgartner et al.   ONCOGENE

A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity

(2012) Xiang Ling et al.   PLoS One

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B

(2012) R W Rooswinkel et al.   Cell Death & Disease

What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?

(2012) L. Sellner et al.   Current Hematologic Malignancy Reports

Raiding the pharmacy: genomic screening identifies known chemotherapies as negative regulators of MCL1

(2012) Lukas W Pfannenstiel et al.   Genome Medicine

miR-193b Regulates Mcl-1 in Melanoma

(2011) Jiamin Chen et al.   AMERICAN JOURNAL OF PATHOLOGY

Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction

(2011) Patricia Gomez-Bougie et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

(2011) S. M. Schoenwaelder et al.   BLOOD

Akt-Dependent Glucose Metabolism Promotes Mcl-1 Synthesis to Maintain Cell Survival and Resistance to Bcl-2 Inhibition

(2011) J. L. Coloff et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

3-Thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) Based Molecules as Potent, Dual Inhibitors of B-Cell Lymphoma 2 (Bcl-2) and Myeloid Cell Leukemia Sequence 1 (Mcl-1): Structure-Based Design and Structure−Activity Relationship Studies

(2011) Zhichao Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

(2011) J. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death

(2011) Domagoj Vucic et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

(2011) T. N. Chonghaile et al.   SCIENCE

ABT-737 synergizes with Bortezomib to kill melanoma cells

(2011) S. N. Reuland et al.   Biology Open

Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance

(2010) K. J. Campbell et al.   BLOOD

Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo

(2010) Clint Mitchell et al.   CANCER BIOLOGY & THERAPY

Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3

(2010) K.-F. Chen et al.   CLINICAL CANCER RESEARCH

MCL-1 is a stress sensor that regulates autophagy in a developmentally regulated manner

(2010) Marc Germain et al.   EMBO JOURNAL

Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells

(2010) M. Baou et al.   HAEMATOLOGICA

A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1

(2010) Zhichao Zhang et al.   INTERNATIONAL JOURNAL OF CANCER

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax)

(2010) L. T. Lam et al.   MOLECULAR CANCER THERAPEUTICS

Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells

(2010) David Reynoso et al.   Molecular Oncology

The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer

(2010) Michelle L Stewart et al.   Nature Chemical Biology

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

(2010) H Zhang et al.   ONCOGENE

Preclinical Studies of Apogossypolone, a Novel Pan Inhibitor of Bcl-2 and Mcl-1, Synergistically Potentiates Cytotoxic Effect of Gemcitabine in Pancreatic Cancer Cells

(2010) Sanjeev Banerjee et al.   PANCREAS

Natural Proteasome Inhibitor Celastrol Suppresses Androgen-Independent Prostate Cancer Progression by Modulating Apoptotic Proteins and NF-kappaB

(2010) Yao Dai et al.   PLoS One

BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program

(2010) D. Ren et al.   SCIENCE

Regulation of heat-induced apoptosis by Mcl-1 degradation and its inhibition by Hsp70

(2009) A R Stankiewicz et al.   CELL DEATH AND DIFFERENTIATION

Different forms of cell death induced by putative BCL2 inhibitors

(2009) M Vogler et al.   CELL DEATH AND DIFFERENTIATION

Antagonism of Beclin 1-dependent autophagy by BCL-2 at the endoplasmic reticulum requires NAF-1

(2009) Natasha C Chang et al.   EMBO JOURNAL

DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy

(2009) Einat Zalckvar et al.   EMBO REPORTS

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines

(2009) Paola Ulivi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Stepwise Activation of BAX and BAK by tBID, BIM, and PUMA Initiates Mitochondrial Apoptosis

(2009) Hyungjin Kim et al.   MOLECULAR CELL

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Alteration of the Mitochondrial Apoptotic Pathway Is Key to Acquired Paclitaxel Resistance and Can Be Reversed by ABT-737

(2008) O. Kutuk et al.   CANCER RESEARCH

A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells

(2008) M Vogler et al.   CELL DEATH AND DIFFERENTIATION

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

(2008) M Vogler et al.   CELL DEATH AND DIFFERENTIATION

Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

(2008) A. R. Shoemaker et al.   CLINICAL CANCER RESEARCH

Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model

(2008) Alan A Arnold et al.   Molecular Cancer

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

JNK1-Mediated Phosphorylation of Bcl-2 Regulates Starvation-Induced Autophagy

(2008) Yongjie Wei et al.   MOLECULAR CELL

BAX activation is initiated at a novel interaction site

(2008) Evripidis Gavathiotis et al.   NATURE

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE